Association Between Genetic Polymorphisms and Type 2 Asthma in Children (SNP)

February 18, 2025 updated by: LI-HONG SUN, Guangzhou Institute of Respiratory Disease

Association Between Cytokines Gene Single Nucleotide Polymorphisms and Type 2 Inflammatory Asthma in Children

To further understand the role of gene single nucleotide polymorphism (SNP) in the occurrence of type 2 inflammation-related asthma in children by analyzing the gene single nucleotide polymorphism (SNP), lung function and type 2 inflammation indicators of children diagnosed with asthma in outpatient and inpatient. To provide a theoretical basis for the study of personalized treatment and prevention strategies for asthma.

Study Overview

Status

Recruiting

Conditions

Detailed Description

Type of study:

This was a prospective, randomized case-control design.To investigate the role of genetic single nucleotide polymorphisms (SNPs) in children with type 2 asthma, and the effects of SNPs on type 2 inflammatory markers and pulmonary function indicators.

Methods:

Children with asthma who were treated at our pediatric respiratory specialty clinic and who met the criteria for type 2 inflammation were included in the case group (Type 2 inflammation was considered to be present if any of the following conditions were present: Fraction of exhaled nitric oxide(FeNO)≥20ppb；Blood eosinophilcount≥350/ul；Percentage of sputum eosinophils>3%; Asthma is caused by inhaled allergens.). The control group is healthy children who underwent physical examination. To compare the differences of single nucleotide polymorphisms (SNPs) between children with type 2 asthma and healthy children, and to explore the risk factors of type 2 asthma.

The differences of indicators between different genotypes were compared, including type 2 inflammation indicators (including Fraction of exhaled nitric oxide(FeNO)、Blood eosinophil count、Percentage of sputum eosinophils and Serum total immunoglobulin E) and pulmonary function indicators(Forced expiratory volume in one second(FEV1)、Forced vital capacity(FVC)、Ratio of forced expiratory volume in one second to forced vital capacity(FEV1/FVC) and Peak expiratory flow(PEF)).

Study Type

Observational

Enrollment (Estimated)

300

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Name: Lihong Sun, M.D.
Phone Number: 13719240285
Email: sunlihong9797@126.com

Study Contact Backup

Name: Lanying Cheng
Phone Number: 15918742726
Email: chenglanyingmed@163.com

Study Locations

China
- Guangdong
  - Guangzhou, Guangdong, China, 510120
    - Recruiting
    - Guangzhou Institute of Respiratory Disease
    - Contact:
      
      Lihong Sun, master
      
      Phone Number: +86-13719240285
      
      Email: sunlihong9797@126.com

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

Child

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Children with asthma, aged 3-14 years, attending our hospital.

Description

Inclusion Criteria:

All children with asthma diagnosis accord with the GINA in 2023 edition;
Other diseases that could cause wheezing and cough were excluded, such as acute laryngitis, diphtheria, congenital airway abnormalities, and tracheal foreign bodies;
In front of the hospital 2 weeks without antibiotics, systemic hormone medication history;
There were no other complications, such as congenital heart disease, pneumonia, gastroesophageal reflux disease, muscle dysplasia, etc.

Exclusion Criteria:

Children who had taken immunosuppressants, antibiotics and other drugs for a long time before admission;
Children with primary immunodeficiency disease;
The children and their families failed to cooperate or refused the experimental observation.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Number of groups / cohorts

Cohorts and Interventions

Group / Cohort
Case group Diagnosis of asthma children
Control group Physical health of children

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
type 2 inflammation indicators Time Frame: Outpatient visits for the first time	Fraction of exhaled nitric oxide(FeNO)、Blood eosinophil count、Percentage of sputum eosinophils and Serum total immunoglobulin E	Outpatient visits for the first time
pulmonary function indicators Time Frame: Outpatient visits for the first time	Forced expiratory volume in one second(FEV1)、Forced vital capacity(FVC)、Ratio of forced expiratory volume in one second to forced vital capacity(FEV1/FVC) and Peak expiratory flow(PEF)	Outpatient visits for the first time
single nucleotide polymorphism Time Frame: Outpatient visits for the first time	Differences in SNPs of genes detected in children's blood samples	Outpatient visits for the first time

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Guangzhou Institute of Respiratory Disease

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 30, 2024

Primary Completion (Estimated)

December 30, 2025

Study Completion (Estimated)

December 30, 2025

Study Registration Dates

First Submitted

October 3, 2024

First Submitted That Met QC Criteria

February 18, 2025

First Posted (Actual)

March 25, 2025

Study Record Updates

Last Update Posted (Actual)